Contact Us
1-800-639-0643
Navigation
Contact Us
544 Egerton St
London ON, N5W 3Z8
T: 1-800-639-0643
F: 519-434-4382
Press Release
Stellar Pharmaceuticals Reports Second Quarter 2011 Financial Results
LONDON, ONTARIO -- (MARKET WIRE) -- Aug 15, 2011 -- Stellar Pharmaceuticals Inc. (OTCQB: SLXCF) ("Stellar" or "the Company"), a Canadian pharmaceutical developer and marketer of high quality, cost-effective products for select health care markets, today announced financial results for the period ended June 30, 2011. In this press release, all dollar amounts are expressed in Canadian currency and results are reported in accordance with United States generally accepted accounting principles (U.S. GAAP).
Q2-2011 Financial Highlights
-- International product revenues grew by 90.7%% -- Domestic product revenues grew by 4.2% -- Cost of sales down to 24.6% compared to 34.6% in 2010For the three month period ended June 30, 2011, total revenues from all sources decreased by 14.6% to $1,072,700, compared to $1,255,800 in the same period during 2010. This differential was due to a 98.6% decrease in royalty and licensing revenues to $6,200 for the three month ended June 30, 2011 compared to $444,100 in the same period during 2010. However, product sales for both domestic and international markets increased by 4.2% and 90.7%, respectively, for the three month period ended June 30, 2011.
For the six month period ended June 30, 2011, total revenues from all sources decreased by 6.9% to $1,706,700, compared to $1,833,700 for the same period in 2010.
Total expenses for the three month period ended June 30, 2011 increased 22.8% or $139,900, compared to the same period in 2010. Total expenses for the six month period end June 30, 2011 increased 24.6% or $301,400, compared to the same period in 2010.
Factors contributing to the decrease in net income loss of $244,490 for the six month period ended June 30, 2011, compared to the same period in 2010, were several non-cash transactions, including:
-- share option expense of $91,000 (2010 - 51,400), of which $21,700 (2010
- $nil) related to options which fully vested upon the retirement of an
officer of the Company
-- amortization expense of $55,100 (2010 - $57,600)
-- warrant liability expense of $64,300 (2010 - $nil) related to the re-
valuation of warrants issued in the October 2010 private placement
-- foreign currency exchange expense of $55,200 (2010 - $15,500)
The Company's net income for the second quarter of 2011 was $58,400 compared to $360,800 during the same period in 2010. As noted above, the net income for the three month period ended June 30, 2011 included $444,100 of royalty and licensing revenues, compared to $6,200 for the same period in 2011, which accounted for the deferential in profit. Although these revenues are an important part of the Company's business, the Company is encouraged by the increases in sales noted in both the international and domestic markets as these are the driving forces in growing the Company.
Stellar Q2 2011 Results
At June 30, 2011 the Company had $3.5 million in cash and cash equivalents, a decrease of $0.9 million over the December 31, 2010 balance of $4.4 million. A significant portion of this decrease was attributed to a $0.4 million retirement payout to an executive office of the Company.
Arnold Tenney, Stellar's President and Chief Executive Officer, commented, "Stellar ended the second quarter of 2011, in a strong financial position, with increases this quarter, in both international and Canadian product sales, no short or long tem debt and working capital of $4.5 million. The Company continues to evaluate all opportunities, including strategic partnerships, to improve product growth and our position in both Canada and international markets."
About Stellar Pharmaceuticals Inc.
Stellar has developed and is marketing direct in Canada, and in countries around the world through out-license agreements, three products based on its core polysaccharide technology: NeoVisc® and NeoVisc® Single Dose, for the symptomatic treatment of osteoarthritis; and Uracyst®, its patented technology for the treatment of interstitial cystitis (IC), an inflammatory disease of the urinary bladder wall. Both NeoVisc and Uracyst have their CE Mark certification for the European Community. Stellar also has an in-licensing agreement for NMP22® BladderChek®, a proteomics-based diagnostic test for the diagnosis and monitoring of bladder cancer. For more information, please visit the company's website at www.stellarpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations, to attract and retain qualified professionals, technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.
CONDENSED INTERIM FINANCIAL STATEMENTS
STELLAR PHARMACEUTICALS INC.
CONDENSED INTERIM BALANCE SHEETS
(Expressed in Canadian dollar)
(Unaudited)
As at As at
June 30, December 31,
CURRENT 2011 2010
------------------------------
Cash and cash equivalents $ 3,453,867 $ 4,352,285
Accounts receivable, net of allowance of $nil
(2010 - $nil) 567,116 493,370
Inventories 725,466 611,676
Taxes recoverable 18,456 -
Loan receivable 15,814 15,814
Prepaids, deposits and sundry receivables 154,635 99,433
------------------------------
Total current assets 4,935,354 5,572,578
PROPERTY, PLANT AND EQUIPMENT, net 1,520,851 1,568,729
OTHER ASSETS 156,591 139,287
------------------------------
Total assets $ 6,612,796 $ 7,280,594
------------------------------
------------------------------
LIABILITIES
CURRENT
Accounts payable $ 175,707 $ 236,420
Accrued liabilities 167,593 557,735
Deferred revenues 9,643 8,645
Product returns liability - 112,500
------------------------------
Total current liabilities 352,943 915,300
LONG TERM WARRANT LIABILITY 281,093 216,823
------------------------------
Total liabilities 634,036 1,132,123
------------------------------
CONTINGENCIES AND COMMITMENTS
SHAREHOLDERS' EQUITY
CAPITAL STOCK
AUTHORIZED
Unlimited Non-voting, convertible redeemable
and retractable preferred shares with no par
value
Unlimited Common Shares with no par value
ISSUED
24,610,042 Common Shares (2010 - 24,585,040) 9,039,764 9,055,982
Additional Paid-in capital options
- outstanding 240,555 211,781
Additional Paid-in capital options
- expired 795,740 733,517
------------------------------
10,076,059 10,001,280
DEFICIT (4,097,299) (3,852,809)
------------------------------
Total shareholders' equity 5,978,760 6,148,471
------------------------------
Total liabilities and shareholders' equity $ 6,612,796 $ 7,280,594
------------------------------
------------------------------
STELLAR PHARMACEUTICALS INC.
CONDENSED STATEMENTS OF OPERATIONS, COMPREHENSIVE INCOME AND DEFICIT
(Expressed in Canadian Dollar)
(Unaudited)
For the For the
Three Month Period Six Month Period
Ended June 30 Ended June 30
2011 2010 2011 2010
----------------------------------------------------
PRODUCT SALES $ 1,066,542 $ 811,752 $ 1,697,819 $ 1,361,262
ROYALTY AND LICENSING
REVENUES 6,163 444,059 8,929 472,426
----------------------------------------------------
TOTAL REVENUES FROM ALL
SOURCES 1,072,705 1,255,811 1,706,748 1,833,688
COST OF PRODUCTS SOLD 261,783 280,717 432,928 484,474
----------------------------------------------------
GROSS PROFIT 810,922 975,094 1,273,820 1,349,214
----------------------------------------------------
EXPENSES
Selling, general and
administrative 698,946 592,585 1,403,002 1,160,517
Research and
development 20,093 9,683 33,771 35,954
Change in warrant
liability 25,024 - 64,271 -
Amortization (non-
manufacturing
property, plant and
equipment) 11,807 13,660 24,120 27,320
----------------------------------------------------
755,870 615,928 1,525,164 1,223,791
----------------------------------------------------
INCOME (LOSS) FROM
OPERATIONS 55,042 359,166 (251,344) 125,423
INTEREST AND OTHER
INCOME 3,353 1,610 6,854 3,123
LOSS ON DISPOSAL OF
EQUIPMENT - - - (15,308)
----------------------------------------------------
INCOME (LOSS) AND
COMPREHENSIVE INCOME
FOR THE PERIOD BEFORE
INCOME TAXES 58,405 360,776 (244,490) 113,238
Current income tax
expense - (29,300) - (29,300)
Future income tax
recovery - 29,300 - 29,300
----------------------------------------------------
NET INCOME (LOSS) AND
COMPREHENSIVE
INCOME (LOSS) FOR THE
PERIOD 58,405 360,776 (244,490) 113,238
DEFICIT, beginning of
period (4,155,704) (4,626,055) (3,852,809) (4,378,517)
----------------------------------------------------
DEFICIT, end of period $ 4,097,299) $(4,265,279) $(4,097,299) $ 4,265,279)
----------------------------------------------------
----------------------------------------------------
EARNINGS (LOSS) PER
SHARE - Basic and
diluted $ 0.00 $ 0.02 $ (0.01) $ 0.00
----------------------------------------------------
----------------------------------------------------
WEIGHTED AVERAGE NUMBER
OF COMMON SHARES
OUTSTANDING - Basic and
diluted 24,602,074 23,485,535 24,593,604 23,482,802
----------------------------------------------------
----------------------------------------------------
STELLAR PHARMACEUTICALS INC.
STATEMENTS OF CASH FLOWS
(Expressed in Canadian dollar)
(Unaudited)
For the For the
Three Month Period Six Month Period
Ended June 30 Ended June 30
2011 2010 2011 2010
--------------------------------------------------
CASH FLOWS FROM (USED IN) OPERATING ACTIVITIES -
Net income (loss) for the period $ 58,405 $ 360,776 $ 244,490)$ 113,238
Items not affecting cash
Amortization 28,340 30,794 55,054 57,579
Current income tax expense (29,300) - (29,300)
Future income tax recovery 29,300 - 29,300
Loss on disposal of equipment - - - 15,308
Change in warrant liability 25,024 - 64,271 -
Issuance of equity instruments for services rendered - 4,000 5,466 4,000
Stock-based compensation 27,262 17,443 90,998 51,390
Change in non-cash operating asset and liabilities (381,116) (434,961) (823,545) (575,882)
--------------------------------------------------
CASH FLOWS (USED IN) OPERATING ACTIVITIES (242,085) (21,948) (852,246) (334,367)
--------------------------------------------------
CASH FLOWS FROM (USED IN) INVESTING ACTIVITIES -
Additions to property, plant and equipment (5,008) (40,290) (5,008) (262,142)
Increase to other assets (15,537) (2,833) (19,480) (10,847)
Proceeds from sale of equipment - - - 12,630
--------------------------------------------------
CASH FLOWS USED IN INVESTING ACTIVITIES (20,545) (43,123) (24,488) (260,359)
--------------------------------------------------
CASH FLOWS USED IN FINANCING ACTIVITIES -
Stock options exercised - 69,000 - 69,000
Share issuance costs (21,684) - (21,684) -
--------------------------------------------------
CASH FLOWS FROM (USED IN) FINANCING ACTIVITIES (21,684) 69,000 (21,684) 69,000
--------------------------------------------------
CHANGE IN CASH AND CASH EQUIVALENTS (284,314) 3,929 (898,418) (525,726)
CASH AND CASH EQUIVALENTS,
Beginning of period 3,738,181 1,795,557 4,352,285 2,325,212
--------------------------------------------------
CASH AND CASH EQUIVALENTS,
End of period $3,453,867 $ 1,799,486 $3,453,867 $ 1,799,486
--------------------------------------------------
--------------------------------------------------
Contacts: Stellar Pharmaceuticals Inc. Arnold Tenney President & CEO (519) 434-1540 arnoldt@stellarpharma.com www.stellarpharma.com